These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. FDA approves memantine drug for treating AD. Am J Alzheimers Dis Other Demen; 2003; 18(6):329-30. PubMed ID: 14682078 [No Abstract] [Full Text] [Related]
4. Factors affecting usage patterns of memantine in Alzheimer disease. Lerner AJ; McClendon MJ; Sami SA; Ogrocki PK; Adams KB; Smyth KA Alzheimer Dis Assoc Disord; 2008; 22(2):137-43. PubMed ID: 18525285 [TBL] [Abstract][Full Text] [Related]
5. Memantine: new preparation. Poor evaluation and uncertain benefit in Alzheimer's disease. Prescrire Int; 2003 Dec; 12(68):203-5. PubMed ID: 14986682 [TBL] [Abstract][Full Text] [Related]
6. Advancing Alzheimer's disease drug review as a national priority. Perry DP Alzheimers Dement; 2009 Mar; 5(2):180-1. PubMed ID: 19328455 [TBL] [Abstract][Full Text] [Related]
7. [Therapy of Alzheimer disease]. Kovács T Neuropsychopharmacol Hung; 2009 Mar; 11(1):27-33. PubMed ID: 19731816 [TBL] [Abstract][Full Text] [Related]
8. [Alzheimer Disease]. Massoud F Can Fam Physician; 2007 Jan; 53(1):50-4. PubMed ID: 17872609 [TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of memantine in moderate-to-severe Alzheimer disease: the evidence to date. Bullock R Alzheimer Dis Assoc Disord; 2006; 20(1):23-9. PubMed ID: 16493232 [TBL] [Abstract][Full Text] [Related]
10. Antidementia agents: what is important in this class. Stefanacci RG; Cafiero AC Manag Care; 2005 May; 14(5 Suppl):11-6. PubMed ID: 15962832 [No Abstract] [Full Text] [Related]
11. First drug for moderate-to-severe Alzheimer's. FDA Consum; 2004; 38(1):3. PubMed ID: 15032183 [No Abstract] [Full Text] [Related]
12. [The clinical relevance of memantine use]. Sobów T Psychiatr Pol; 2004; 38(2):321-30. PubMed ID: 15307296 [TBL] [Abstract][Full Text] [Related]
13. [Effectiveness and tolerance of memantine in general practice]. Krankenpfl J; 2005; 43(1-3):35. PubMed ID: 15912828 [No Abstract] [Full Text] [Related]
14. [Little behavior improvement with memantine]. Potz-Biedermann C Med Monatsschr Pharm; 2005 Nov; 28(11):413-4. PubMed ID: 16309030 [No Abstract] [Full Text] [Related]
15. Update on dementia medications for 2004. Miller CA Geriatr Nurs; 2004; 25(1):56-7. PubMed ID: 14976510 [No Abstract] [Full Text] [Related]
17. [New options for the pharmacotherapy of Alzheimer disease after the approval of memantine? Re the article from DMW 8/2005]. Wellhöfer B Dtsch Med Wochenschr; 2006 Feb; 131(6):284. PubMed ID: 16463237 [No Abstract] [Full Text] [Related]
18. Exacerbation of myoclonus by memantine in a patient with Alzheimer disease. Papageorgiou SG; Kontaxis T; Antelli A; Kalfakis N J Clin Psychopharmacol; 2007 Aug; 27(4):407-8. PubMed ID: 17632233 [No Abstract] [Full Text] [Related]
19. The US Food and Drug Administration Cardiorenal Advisory Panel and the drug approval process. Roden DM; Temple R Circulation; 2005 Apr; 111(13):1697-702. PubMed ID: 15811869 [No Abstract] [Full Text] [Related]
20. Behavioral effects of current Alzheimer's disease treatments: a descriptive review. Cummings JL; Mackell J; Kaufer D Alzheimers Dement; 2008 Jan; 4(1):49-60. PubMed ID: 18631950 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]